Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18660815 | CD73 INHIBITORS | May 2024 | June 2025 | Allow | 14 | 0 | 1 | No | No |
| 18605925 | PROCESS FOR THE PREPARATION OF HIGH PURITY NORBORNENE SILYL ETHERS | March 2024 | April 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18439896 | METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING SALVIANOLIC ACID B | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18414679 | POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS | January 2024 | March 2025 | Allow | 14 | 0 | 1 | Yes | No |
| 18491943 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18374543 | Oligosaccharide Compound for Inhibiting Intrinsic Coagulation Factor X-Enzyme Complex, and Preparation Method Therefor and Uses Thereof | September 2023 | December 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18470776 | PURIFICATION OF TRIMETHYLSILANOL | September 2023 | May 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18469292 | OLIGOSACCHARIDE LINKER, LINKER-PAYLOAD COMPRISING THE SAME AND GLYCAN CHAIN-REMODELED ANTIBODY-DRUG CONJUGATE, PREPARATION METHODS AND USES THEREOF | September 2023 | January 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18369456 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | September 2023 | November 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18459683 | COMPOSITIONS CONTAINING DECITABINE, 5AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOF | September 2023 | January 2025 | Abandon | 16 | 1 | 1 | No | No |
| 18365920 | AFFINITY MEDICANT CONJUGATE | August 2023 | January 2025 | Allow | 18 | 2 | 1 | No | No |
| 18330757 | METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONS | June 2023 | May 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18328433 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | June 2023 | March 2025 | Allow | 21 | 1 | 1 | No | No |
| 18203678 | POLYMORPHIC FORMS OF RAD1901-2HCL | May 2023 | April 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18198258 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | May 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18315446 | CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS | May 2023 | October 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18306601 | CANCER TREATMENT | April 2023 | July 2024 | Allow | 15 | 3 | 0 | No | Yes |
| 18138432 | DEOXYNUCLEOSIDE THERAPY FOR DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18189943 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | March 2023 | May 2025 | Allow | 26 | 1 | 1 | No | No |
| 18124697 | AMINOCARBONYLCARBAMATE COMPOUNDS | March 2023 | April 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18120596 | FREEZE-DRIED ALGINIC ACID PREPARATION | March 2023 | August 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18172731 | Photochemical Separations and Compositions | February 2023 | May 2025 | Allow | 26 | 2 | 0 | No | No |
| 18106149 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | February 2023 | February 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18161136 | COMPOSITIONS AND METHODS OF TREATMENT USING NICOTINAMIDE MONONUCLEOTIDE | January 2023 | February 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18101258 | HEPATITIS B ANTIVIRAL AGENTS | January 2023 | February 2024 | Allow | 12 | 1 | 0 | No | No |
| 18152993 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | January 2023 | March 2025 | Allow | 26 | 1 | 1 | No | No |
| 18087587 | ANTIMICROBIAL ORGANOSILANES | December 2022 | April 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18068346 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 17989131 | SILYLATED ORGANOMODIFIED COMPOUNDS | November 2022 | October 2024 | Allow | 23 | 2 | 2 | Yes | No |
| 17979450 | HYALURONAN CONJUGATES AND USES THEREOF | November 2022 | August 2024 | Allow | 21 | 2 | 0 | No | No |
| 18051125 | CD73 INHIBITORS | October 2022 | February 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 17976101 | MUSCLE REGENERATION | October 2022 | January 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18049341 | PROCESS FOR PREPARING GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES | October 2022 | February 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18048504 | TREATMENTS OF PROSTATE CANCER | October 2022 | October 2023 | Allow | 12 | 2 | 0 | No | No |
| 17917562 | Method for the dehydrogenation and methylation of silanes with methyl chloride | October 2022 | December 2024 | Allow | 26 | 1 | 0 | No | No |
| 17995196 | IMMUNOMODULATORS | September 2022 | June 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17946416 | INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY | September 2022 | June 2025 | Allow | 33 | 2 | 1 | Yes | Yes |
| 17801628 | NON-CRYOGENIC SYNTHESIS OF HETEROATOM-BRIDGE PRECURSORS OF METAL-LIGAND COMPLEX CATALYSTS | August 2022 | May 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17893777 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING CORONARY DISORDERS | August 2022 | April 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17800211 | METHOD OF PREPARING SILANOLS WITH SELECTIVE CYTOCHROME P450 VARIANTS AND RELATED COMPOUNDS AND COMPOSITIONS | August 2022 | October 2024 | Allow | 26 | 1 | 0 | No | No |
| 17820242 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | August 2022 | May 2023 | Allow | 8 | 1 | 0 | No | No |
| 17878747 | CANCER TREATMENTS | August 2022 | March 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17795207 | METHOD FOR PRODUCING HALOGENATED HYDROCARBON MAGNESIUM COMPOUND AND METHODS FOR PRODUCING TERTIARY ALCOHOL COMPOUND AND ORGANOSILICON COMPOUND | July 2022 | January 2025 | Allow | 30 | 1 | 1 | No | No |
| 17871515 | COMPOSITIONS COMPRISING CITRULLINE AND LEUCINE AND THEIR USE IN THE TREATMENT OF DIABETES AND METABOLIC SYNDROME | July 2022 | December 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17869352 | SEMICONDUCTING LIGHT EMITTING MATERIAL | July 2022 | October 2024 | Abandon | 27 | 1 | 2 | No | No |
| 17859953 | SILICON PRECURSOR MATERIALS, SILICON-CONTAINING FILMS, AND RELATED METHODS | July 2022 | September 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17809239 | PREPARATION METHOD OF FUNCTIONAL SILANES | June 2022 | January 2023 | Allow | 7 | 1 | 0 | No | No |
| 17848466 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 10 | 0 | 0 | No | No |
| 17848456 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 10 | 0 | 0 | No | No |
| 17848468 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 10 | 0 | 0 | Yes | No |
| 17848462 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 11 | 0 | 0 | No | No |
| 17787806 | FUNCTIONALISATION OF 1,3-ALPHA-DIENES (I) | June 2022 | April 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17786570 | SELECTIVE PREPARATION OF VINYL- AND ETHYL-FUNCTIONALIZED CHLOROSILANES | June 2022 | February 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17842042 | NICOTINAMIDE RIBOSIDE FOR USE IN TREATING OR PREVENTING LIVER DAMAGE | June 2022 | August 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17784082 | PROCESS FOR SYNTHESIZING ALKENYL DISILOXANE | June 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17833780 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | June 2022 | March 2024 | Allow | 22 | 1 | 1 | No | No |
| 17805479 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | June 2022 | March 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17805634 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | June 2022 | April 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17828591 | HYDROGEN-BONDED ORGANIC FRAMEWORK (HOF) FOR WATER UPTAKE | May 2022 | August 2022 | Allow | 2 | 0 | 0 | No | No |
| 17780559 | PROCESS FOR PREPARING TRIMETHYLCHLOROSILANE | May 2022 | February 2025 | Allow | 33 | 2 | 0 | No | No |
| 17749293 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | May 2022 | December 2023 | Allow | 19 | 1 | 0 | No | No |
| 17738435 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | May 2022 | January 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17728698 | TREATMENT OF MITOCHONDRIAL DISEASES | April 2022 | January 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17726415 | Method and Composition for Treating Seizure Disorders | April 2022 | December 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17725080 | PROCESS FOR THE SYNTHESIS OF OLIGOMERIC SILOXANE HAVING SULFONE MOIETY, AND SILICON-CONTAINING COMPOUNDS HAVING SULFONE MOIETY | April 2022 | August 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17659537 | METFORMIN COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | April 2022 | September 2023 | Allow | 17 | 1 | 0 | No | No |
| 17723168 | ANTIMICROBIAL ORGANOSILANES | April 2022 | September 2024 | Allow | 29 | 0 | 1 | No | No |
| 17722011 | THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES | April 2022 | January 2024 | Allow | 21 | 2 | 0 | No | No |
| 17711376 | METHOD FOR PREPARING HALOSILANE COMPOUNDS | April 2022 | April 2023 | Allow | 12 | 1 | 0 | No | No |
| 17697306 | TREATMENTS OF PROSTATE CANCER | March 2022 | September 2022 | Allow | 6 | 1 | 1 | Yes | No |
| 17690323 | 5-BROMO-INDIRUBINS | March 2022 | November 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17684248 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN APPEARANCE | March 2022 | February 2024 | Allow | 23 | 1 | 1 | No | No |
| 17673061 | Compositions and Methods for Lowering Triglycerides Without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy | February 2022 | October 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17666686 | PREPARATION OF LANTHANIDE-CONTAINING PRECURSORS AND DEPOSITION OF LANTHANIDE-CONTAINING FILMS | February 2022 | July 2023 | Allow | 18 | 1 | 1 | No | No |
| 17665282 | HALOGEN FREE SYNTHESES OF AMINOSILANES BY CATALYTIC DEHYDROGENATIVE COUPLING | February 2022 | May 2023 | Allow | 16 | 0 | 1 | No | No |
| 17591978 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | February 2022 | April 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17586387 | COMPOSITIONS CONTAINING DECITABINE, 5AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOF | January 2022 | June 2023 | Allow | 16 | 1 | 0 | No | No |
| 17577252 | SYNTHETIC COMPOSITION | January 2022 | January 2024 | Abandon | 24 | 1 | 1 | Yes | No |
| 17576767 | AFFINITY MEDICANT CONJUGATE | January 2022 | February 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17573143 | METABOLITES OF BICTEGRAVIR | January 2022 | September 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17560485 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | December 2021 | January 2023 | Allow | 13 | 1 | 0 | No | No |
| 17559456 | METHODS FOR CO-ISOLATION OF NUCLEIC ACIDS AND PROTEINS | December 2021 | June 2023 | Allow | 18 | 0 | 0 | No | No |
| 17557649 | METHOD OF TREATING CANCER | December 2021 | November 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17551922 | METHODS OF TREATMENT | December 2021 | September 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17551252 | HIGH PURITY POLYSILOXANE MACROMERS AND METHOD FOR MAKING THE SAME | December 2021 | June 2025 | Abandon | 42 | 4 | 1 | No | No |
| 17546207 | METABOLITES OF GLP1R AGONISTS | December 2021 | April 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17617032 | PROCESS FOR PURIFYING SILICON COMPOUNDS | December 2021 | March 2024 | Allow | 28 | 0 | 0 | Yes | No |
| 17544847 | INHALATION DELIVERY METHODS AND COMPOSITIONS FOR VITAMIN B12 | December 2021 | May 2024 | Allow | 30 | 2 | 1 | Yes | Yes |
| 17544514 | MICELLE COMPRISING BENZIMIDAZOLE-CARBOHYDRATE CONJUGATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTICANCER AGENT OR ANTIVIRAL AGENT COMPRISING THE SAME | December 2021 | January 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17535314 | METHOD OF CROSSLINKING GLYCOSAMINOGLYCANS | November 2021 | June 2023 | Allow | 19 | 1 | 1 | No | No |
| 17533559 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | November 2021 | July 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17454748 | METHOD FOR TREATING AMYLOIDOGENIC DISEASE | November 2021 | August 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17300780 | Increased isoelectric points for preventive compounds for covid 19 treatments | November 2021 | November 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17519486 | METHODS OF TREATMENT USING 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | November 2021 | March 2023 | Allow | 16 | 0 | 1 | No | No |
| 17516600 | IDENTIFICATION AND TREATMENT OF T-CELL EPITOPES OF SHORT H2A ONCOHISTONES | November 2021 | June 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17607886 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | October 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17511888 | METHODS FOR IMPROVING ANTI-OXIDATION AND PREVENTING/TREATING DISEASES USING HYPO-ACYLATED LIPOPOLYSACCHARIDE | October 2021 | December 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17606186 | GLP-1 SECRETION-PROMOTING COMPOSITION | October 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17606181 | COMPOSITION FOR PROMOTING GLP-1 SECRETION | October 2021 | June 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17606204 | COMBINATION THERAPIES FOR CANCER TREATMENT | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BAKSHI, PANCHAM.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner BAKSHI, PANCHAM works in Art Unit 1623 and has examined 696 patent applications in our dataset. With an allowance rate of 73.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner BAKSHI, PANCHAM's allowance rate of 73.7% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by BAKSHI, PANCHAM receive 1.49 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BAKSHI, PANCHAM is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +31.1% benefit to allowance rate for applications examined by BAKSHI, PANCHAM. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.1% of applications are subsequently allowed. This success rate is in the 64% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 38.4% of cases where such amendments are filed. This entry rate is in the 51% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 22.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 81.5% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 40.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.